Search Results
Your search for ASCO matches 20057 pages
Showing 401 - 450I Don’t Want Cancer to Define Me
Except for a series of unexplained multiple broken bones and inexplicable excruciating pain in my right hip and leg, I had no other hallmarks of multiple myeloma when I was diagnosed with the disease at age 48 in 2014. My blood test values were all normal, and I didn’t have anemia or kidney damage. ...
Implementation of Updated WHO Screening Guidelines Could Reduce Cervical Cancer Mortality by Over 50% in Lower-Income Countries
Investigators have found that implementing the updated World Health Organization (WHO) screening guidelines may effectively reduce the cervical cancer mortality rate in patients residing in low- and middle-income countries, according to two recent studies published by Simms et al and Hall et al in...
New Findings Challenge Widely Accepted Beliefs About the Relative Efficacy of Opioids in Treating Cancer Pain
Investigators have uncovered concerningly large gaps in evidence regarding the true benefits of opioids for pain relief in patients with cancer, according to a novel study published by Shaheed et al in CA: A Cancer Journal for Clinicians. The new findings could challenge the commonly held view that ...
Community Program Cuts Treatment Delays in Half for Minority and Low-Income Patients
A program aimed at improving access to high-quality cancer care has significantly increased adherence to cancer treatment among minority and low-income communities, according to data presented at the 2023 ASCO Quality Care Symposium.1 The introduction of the ALCANCE-PLUS program in Monterey County, ...
The Power of Patient Advocacy: 10-Year Study Reveals Increased Survival Rates With Enhanced Advance Care Planning
A decade-long journey toward improving end-of-life care for patients with advanced cancer has demonstrated positive effects on survival, health-care use, and cost of care, according to data presented at the 2023 ASCO Quality Care Symposium.1 Post hoc analysis of an advance care planning...
All Adult Oncologists Are Geriatric Oncologists
The data developed over the past few years have overwhelmingly favored geriatric assessment as part of the routine care for older patients with cancer. It has become the standard of care. ASCO has recently published a Practical Geriatric Assessment to aid in the implementation of this vital...
Expert Point of View: Susan Faye Dent, MD
In a joint ASCO/ICOS (International Cardio-Oncology Society) session presented at the 2023 Global Cardio-Oncology Summit, Dr. Anita Arnold and Dr. Krishnan Bhaskaran discussed the importance of understanding the impact of cancer therapy on the cardiovascular health of women. Medical oncologist...
Cardiovascular Health of Women Treated for Cancer: Understanding the Long-Term Risks
At the 2023 Global Cardio-Oncology Summit in Madrid, in a joint session with ASCO and the International Cardio-Oncology Society, Anita Arnold, DO, FACC, MBA, Director, Noninvasive Cardiology, and Director of Cardio-Oncology, Lee Memorial Health Systems, Fort Myers, Florida, discussed the...
Psilocybin-Assisted Therapy May Reduce Depressive Symptoms in Patients With Cancer
Researchers have uncovered that psilocybin-assisted therapy may be safe and effective in patients with cancer and comorbid major depressive disorder, according to two novel studies published by Agrawal et al and Beaussant et al in Cancer. Background Psilocybin is a hallucinogenic chemical found in...
Lung Nodule Program May Help Detect Cancer in Patients Age-Ineligible for Lung Cancer Screening
Researchers have found that adopting a Lung Nodule Program may increase early lung cancer detection in patients who are not eligible for lung cancer screening under existing age-eligibility criteria, according to a recent study published by Liao et al in the Journal of Thoracic Oncology. ...
W. Kimryn Rathmell, MD, PhD, Begins Work as 17th Director of the NCI
On December 18, W. Kimryn Rathmell, MD, PhD, began her work as the 17th Director of the National Cancer Institute (NCI). Dr. Rathmell was selected by President Biden to succeed Monica M. Bertagnolli, MD, FACS, FASCO, who left NCI to become the Director of the National Institutes of Health (NIH) on...
GLP-1 Receptor Agonists May Reduce Risk of Colorectal Cancer in Patients With High BMI and Diabetes
Glucagon-like peptide 1 (GLP-1) receptor agonists may be effective at reducing the risk of colorectal cancer in patients with a higher body mass index (BMI) and diabetes, according to a recent study published by Wang et al in JAMA Oncology. Background Obesity is a chronic health condition that...
William G. Wierda, MD, PhD, on Use of Pirtobrutinib for Richter Transformation: Updated Efficacy and Safety Results
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the phase I/II BRUIN study, which shows encouraging response and overall survival in patients with Richter transformation. Although this condition remains a challenging diagnosis, pirtobrutinib...
Mikkael A. Sekeres, MD, on Therapies for Hematologic Cancers: Is More or Less Better?
Mikkael A. Sekeres, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, reviews key abstracts from ASH 2023 on treatment of myelofibrosis, chronic lymphocytic leukemia, large B-cell lymphoma, and acute myeloid leukemia (Abstracts 620, 631, 781,...
Darren Denjay Pan, MD, on Multiple Myeloma: Inflammatory Biomarkers and Outcomes After CAR T-Cell Therapy
Darren Denjay Pan, MD, of Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, discusses his findings on risk assessment of CAR T-cell therapy for patients with multiple myeloma. Higher fibrinogen and ferritin values at baseline were associated with inferior overall survival...
Hope S. Rugo, MD, on Advanced Breast Cancer: Patient-Reported Outcomes From the CAPItello-291 Trial
Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient-reported outcomes from the phase III CAPItello-291 study; the trial centered on adding capivasertib to fulvestrant in patients with aromatase inhibitor–resistant,...
Eleftherios P. Mamounas, MD, on Locoregional Irradiation, Axillary Lymph Node Involvement, and Conversion to Negative Nodes
Eleftherios P. Mamounas, MD, of Orlando Health Cancer Institute, discusses primary outcomes from the NRG Oncology/NSABP B-51/RTOG 1304 study of locoregional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant ...
Daniel Kates-Harbeck, MD Candidate, and Nadia Harbeck, MD, PhD, on Personalizing Breast Cancer Management With AI: Novel Approach to Predicting Outcomes
Nadia Harbeck, MD, PhD, of LMU University Hospital and Ludwig Maximilian University of Munich, and Daniel Kates-Harbeck, of the West German Study Group and an MD Candidate at Ludwig Maximilian University of Munich, discuss a learning-based neural network developed by Mr. Kates-Harbeck to predict...
Luca Gianni, MD, on Locally Advanced, HER2-Positive Breast Cancer: New Data on Neoadjuvant Therapy and Atezolizumab
Luca Gianni, MD, of Milan’s Fondazione Michelangelo, discusses findings from the APTneo Michelangelo trial, which showed that adding atezolizumab to chemotherapy and trastuzumab plus pertuzumab did not significantly increase the rate of pathologic complete response (pCR) in women with HER2-positive ...
Oleg Gluz, MD, on Response to Endocrine Therapy: Findings From the ADAPTcycle Trial
Oleg Gluz, MD, of the West German Study Group and Breast Center Niederrhein, discusses the impact of age and ovarian function suppression in response to preoperative endocrine treatment for both pre- and postmenopausal patients with early-stage breast cancer. He describes ways in which the outcome...
Pieter Sonneveld, MD, PhD, on Newly Diagnosed Multiple Myeloma: Phase III Findings on Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone
Pieter Sonneveld, MD, PhD, of the Netherland’s Erasmus MC Cancer Institute, discusses primary results from the Perseus trial, showing that for patients with newly diagnosed multiple myeloma who are eligible for transplantation, the combination of daratumumab plus bortezomib, lenalidomide, and...
Combination Treatment That Skips Chemotherapy May Be Effective for Older Patients With Philadelphia Chromosome–Positive ALL
Older patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) who were not candidates for the standard treatment of intensive chemotherapy had a median overall survival of 6.5 years on an alternative regimen of dasatinib and blinatumomab, according to long-term results...
First-Line Treatment for Older Patients With Mantle Cell Lymphoma: Venetoclax Plus Standard Chemoimmunotherapy
The phase II PrE0405 trial met its primary endpoint, achieving a complete response rate of 85% in 33 patients with mantle cell lymphoma over age 60 who received bendamustine and rituximab, a standard chemoimmunotherapy regimen, along with venetoclax, which is investigational in this setting. The...
FDA Approves Enfortumab Vedotin-ejfv With Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer
On December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial cancer. The FDA previously granted accelerated approval to this combination for patients...
Bijal D. Shah, MD, on Previously Treated Mantle Cell Lymphoma: New Findings on Brexucabtagene Autoleucel and Pirtobrutinib
Bijal D. Shah, MD, of Moffitt Cancer Center and Research Institute, discusses a matching-adjusted indirect comparison of brexucabtagene autoleucel and pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma who have been previously treated with a BTK inhibitor (Abstract 5136).
Eric J. Small, MD, FASCO, Elected ASCO President for 2025–2026 Term
ASCO has elected Eric J. Small, MD, FASCO, to lead as its President beginning in June 2025. Dr. Small, a long-time ASCO member and volunteer, will take office as President-Elect immediately following the ASCO Annual Business Meeting in Chicago on June 3, 2025. An additional six ASCO members were...
ConcertAI to Acquire CancerLinQ
On December 11, ConcertAI announced the acquisition of CancerLinQ, previously a subsidiary of ASCO. In conjunction with the acquisition, ASCO will maintain a multiyear cooperation agreement with CancerLinQ. Building on CancerLinQ’s mission when launched by ASCO in 2013, this new venture will...
FDA Approves Belzutifan for Advanced Renal Cell Carcinoma
On December 14, the U.S. Food and Drug Administration (FDA) approved belzutifan (Welireg) for patients with advanced renal cell carcinoma following treatment with a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor. LITESPARK-005 Efficacy was...
Understanding Racial and Ethnic Disparities in Modern AML Care After the Approval of Venetoclax
Use of venetoclax may increase survival in non-Hispanic Black patients with acute myeloid leukemia (AML), according to recent findings presented by Wang et al at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 955). Background Although the standard treatment...
Bezuclastinib May Reduce Symptoms in Patients With Nonadvanced Systemic Mastocytosis
The targeted therapy bezuclastinib may be safe and effective at reducing markers of disease burden and improving symptoms in patients with nonadvanced systemic mastocytosis, according to recent findings published by Bose et al at the 2023 American Society of Hematology (ASH) Annual Meeting &...
Use of Elranatamab for Black Patients With Multiple Myeloma
Elranatamab may be safe and effective in Black patients with relapsed or refractory multiple myeloma, according to new findings presented by Varshavsky-Yanovsky et al at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 3333). Background Elranatamab—an...
Danai Dima, MD, on Multiple Myeloma: Update on Safety and Efficacy of Teclistamab
Danai Dima, MD, of the Taussig Cancer Institute, Cleveland Clinic, discusses teclistamab-cqyv, a B-cell maturation antigen approved in October 2022 for patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. Dr. Dima and her team evaluated the...
Jonathon B. Cohen, MD, on Mantle Cell Lymphoma: New Data on Pirtobrutinib
Jonathon B. Cohen, MD, of Winship Cancer Institute, Emory University, discusses safety and efficacy findings from the phase I/II BRUIN study. The trial found that pirtobrutinib continues to demonstrate durable efficacy and a favorable safety profile in heavily pretreated patients with relapsed or...
Revumenib in High-Risk KMT2A-Rearranged Acute Leukemia
Patients with relapsed or refractory acute leukemia with rearrangement in the lysine methyltransferase 2A gene, a genetic marker known as KMT2A, who were treated with revumenib, a small-molecule inhibitor of menin-KMT2A interactions, saw an overall response rate of 63%, according to results from...
Ruxolitinib Plus Navitoclax May Reduce Spleen Volume in Patients With Myelofibrosis
The Janus kinase (JAK) inhibitor ruxolitinib plus the B-cell lymphoma 2 protein inhibitor navitoclax may be twice as effective at spleen volume reduction compared with standard-of-care ruxolitinib monotherapy in adult patients with intermediate- or high-risk myelofibrosis, according to new findings ...
Novel BET Inhibitor for Advanced Myelofibrosis
Researchers may have uncovered a new type of targeted therapy for patients with advanced myelofibrosis, according to new findings presented by Watts et al at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 750). Background Historically, there have been few...
Menin Inhibitors in Patients With Advanced AML and Gene Mutations
Two new studies have demonstrated positive results from novel therapies targeting menin for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with specific gene mutations, according to findings presented by Jabbour et al (Abstract 57) and Issa et al (Abstract 58) at ...
Presence of MRD After Chemotherapy May Predict Benefit From Donor Transplant in NPM1-Mutated AML
Among patients who have acute myeloid leukemia (AML) with genetic mutations in NPM1, those with no residual leukemia cells in the blood based on high-sensitivity testing after two cycles of chemotherapy achieved high rates of overall survival at 3 years and saw no additional survival benefit from...
FDA Approves Eflornithine for Adult and Pediatric Patients With High-Risk Neuroblastoma
On December 13, the U.S. Food and Drug Administration approved eflornithine (Iwilfin), an irreversible inhibitor of ornithine decarboxylase, to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior...
Barbara Pistilli, MD, on HR+, HER2– Advanced Breast Cancer: Update on Capivasertib Plus a CDK4/6 Inhibitor and Fulvestrant
Barbara Pistilli, MD, of France’s Gustave Roussy, discusses a phase Ib analysis from the CAPItello-292 study, which showed capivasertib plus palbociclib plus fulvestrant was tolerable at all dose levels in heavily pretreated patients with hormone receptor–positive, HER2-negative advanced breast...
Sherene Loi, MD, PhD, on Biomarker Results in ER+, HER2– Primary Breast Cancer Following Neoadjuvant Chemotherapy With or Without Nivolumab
Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses an exploratory analysis of CheckMate 7FL which showed that patients with PD-L1–positive, high-risk, estrogen receptor–positive, HER2-negative primary breast cancer may achieve substantial pathologic complete response rates ...
Daratumumab Plus VRd Outperforms VRd Alone for Multiple Myeloma
Newly diagnosed patients with multiple myeloma who received daratumumab along with the standard care regimen of bortezomib, lenalidomide, and dexamethasone (VRd) had significantly higher rates of survival without disease progression compared with those who received VRd alone. Results from the phase ...
Potential Underlying Genetic Mutations Identified in Patients With Myelodysplastic Syndromes
Researchers may have uncovered the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes and other myeloid neoplasms, according to new findings presented by Chaudhry et al at the American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract...
Ibrutinib/Venetoclax in Relapsed/Refractory Mantle Cell Lymphoma
Patients with relapsed or refractory mantle cell lymphoma who received ibrutinib in combination with venetoclax experienced significantly better rates of progression-free survival compared with patients who received ibrutinib and placebo, according to findings from the international phase III...
Novel CAR T-Cell Therapy May Show Early Efficacy in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Early results from a new study have demonstrated that the novel chimeric antigen receptor (CAR) T-cell therapy AT101 resulted in favorable complete response rates at higher dose levels in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, according to new findings simultaneously...
AI Model May Help Distinguish Between Two Rare Hematologic Malignancies
A novel artificial intelligence (AI) model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia, according to new findings presented by Srisuwananukorn et al at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition...
CAR T-Cell Therapy Safe, Feasible for Patients With Lymphoma in Complete Remission Before Cell Therapy Begins
Data presented at the 2023 ASH Annual Meeting & Exposition suggest that chimeric antigen receptor (CAR) T-cell immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins (Abstract 615). While the findings do not answer the...
Sherene Loi, MD, PhD, on Triple-Negative Breast Cancer: Phase II Study Results of Nivolumab, Carboplatin, and Paclitaxel
Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses recent data showing that for patients with stage I/II triple-negative breast cancer, 12 weeks of a neoadjuvant nonanthracycline chemotherapy regimen with nivolumab may be efficacious with either concurrent or lead-in...
Aditya Bardia, MD, MPH, on Early-Stage, High-Risk Breast Cancer: New Data on Pembrolizumab Plus Chemotherapy
Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses phase III findings from the KEYNOTE-756 study, which showed that adding pembrolizumab to chemotherapy increases the pathologic complete response rate and lowers the residual cancer burden in patients with...
Daniel G. Stover, MD, on Early-Stage Breast Cancer: A Biomarker Analysis From the PALLAS Trial
Daniel G. Stover, MD, of The Ohio State University Comprehensive Cancer Center, discusses a biomarker analysis from the PALLAS adjuvant trial, which compared 2 years of the CDK4/6 inhibitor palbociclib with endocrine therapy vs endocrine therapy alone, as adjuvant treatment for patients with stage...
